AbbVie (ABBV) Stock Forecast & Price Target

$194.19

-0.16 (-0.08%)

(As of 10/11/2024 ET)

AbbVie - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
2

Buy
14

Based on 16 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for ABBV.

Consensus Price Target

$198.00
1.96% Upside

According to the 16 analysts' twelve-month price targets for AbbVie, the average price target is $198.00. The highest price target for ABBV is $225.00, while the lowest price target for ABBV is $150.00. The average price target represents a forecasted upside of 1.96% from the current price of $194.19.

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

ABBV Analyst Ratings Over Time

Type	Current Forecast 10/13/23 to 10/12/24	1 Month Ago 9/13/23 to 9/12/24	3 Months Ago 7/15/23 to 7/14/24	1 Year Ago 10/13/22 to 10/13/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$198.00	$191.64	$182.69	$167.33
Forecasted Upside	1.96% Upside	-1.24% Downside	7.29% Upside	13.07% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Bill Gates’s Next Big AI Bet: Stargate (Ad)

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Medical Companies	S&P 500
Consensus Rating Score	2.94	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.95% Upside	10,374.29% Upside	6.83% Upside
News Sentiment Rating	Positive News See Recent ABBV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/10/2024	Truist Financial 2 of 5 stars		Boost Target	Buy ➝ Buy	$210.00 ➝ $215.00	+10.49%
10/9/2024	UBS Group 4 of 5 stars		Boost Target	Neutral ➝ Neutral	$185.00 ➝ $195.00	+0.17%
10/7/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $212.00	+9.75%
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$195.00 ➝ $225.00	+16.22%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/23/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$196.00 ➝ $209.00	+6.05%
Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.
8/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$211.00 ➝ $218.00	+14.81%
8/5/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00	+8.40%
7/26/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $205.00	+12.53%
7/19/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$180.00 ➝ $214.00	+24.50%
7/3/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$190.00 ➝ $190.00	+14.48%
6/5/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$185.00	+14.08%
3/22/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$188.00 ➝ $190.00	+6.41%
2/5/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$181.00 ➝ $189.00	+12.05%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$173.00	+15.89%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$150.00	+5.60%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$170.00 ➝ $160.00	+18.02%
4/5/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/22/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
2/10/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$157.00 ➝ $154.00	+1.83%
2/10/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	+2.89%
2/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	+2.89%
11/8/2022	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$155.00 ➝ $140.00	-7.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:08 PM ET.

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 6, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie offers a competitive dividend yield of 3.24%, providing investors with a steady income stream.
The company has a diverse portfolio of pharmaceutical products, including Humira, Skyrizi, and Rinvoq, catering to various medical conditions and diseases.
Recent analyst ratings have been overwhelmingly positive, with an average target price of $191.64, indicating strong growth potential.
AbbVie's stock price has shown resilience, trading at $191.16, near its 1-year high of $199.95, reflecting investor confidence.
With a strong buy rating from William Blair and an outperform rating from BMO Capital Markets, AbbVie is well-positioned for future growth.

AbbVie
Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

AbbVie's dividend payout ratio is currently high at 183.98%, indicating that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment for growth.
Chairman Richard A. Gonzalez has been actively selling AbbVie shares, raising concerns about insider sentiment and future performance.
The stock's price-to-earnings ratio of 57.04 and a PEG ratio of 2.65 suggest that the stock may be overvalued compared to industry peers.
While AbbVie has a strong product pipeline, there may be regulatory risks associated with drug approvals and patent expirations in the pharmaceutical industry.
AbbVie's beta of 0.64 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors seeking higher returns.

ABBV Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $198.00, with a high forecast of $225.00 and a low forecast of $150.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.
: According to analysts, AbbVie's stock has a predicted upside of 1.96% based on their 12-month stock forecasts.
: Over the previous 90 days, AbbVie's stock had 1 upgrade by analysts.
: AbbVie has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Morgan Stanley, Piper Sandler, TD Cowen, Truist Financial, UBS Group, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.94 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ABBV compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

AI Expert Reveals New Pick (Ad)

Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right now

Click here to see why

This page (NYSE:ABBV) was last updated on 10/12/2024 by MarketBeat.com Staff

From Our Partners